Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • Dec. 7, 2011, 6:14 PM
    Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon.
    | 1 Comment
  • Dec. 6, 2011, 1:16 PM
    Amgen (AMGN -0.2%) announces that it has struck an agreement with the FDA to modify its Nplate treatment designed to treat an immune system disorder that attacks blood elements. "The FDA has now concluded that enrollment in a restricted distribution program is no longer necessary to prescribe or receive Nplate."
    | Comment!
  • Nov. 18, 2011, 3:34 PM
    Dialysis clinic operator DaVita (DVA +3.1%) signs a new, seven-year agreement to receive Amgen's (AMGN -0.5%) anti-anemia drug Epogen. In an SEC filing, Amgen discloses that the Epogen it supplies will meet at least 90% of DaVita's requirements for erythropoiesis stimulating agents in clinics in the U.S. and Puerto Rico.
    | Comment!
  • Nov. 14, 2011, 3:50 PM
    An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via an injected monoclonal antibody designed to inhibit the action of a protein called PCSK9, which is involved with the regulation of LDL (bad cholesterol). Sanofi (SNY) and Regeneron (REGN) are believed to have progressed the most in developing products that target PCSK9.
    | Comment!
  • Nov. 8, 2011, 4:12 PM
    Amgen (AMGN -0.7%) underperformed a little today after a U.S. appeals court gave a green light to a securities class-action lawsuit accusing the company of failing to disclose safety information for two anemia drugs, and of promoting unauthorized uses of its products.
    | Comment!
  • Nov. 7, 2011, 9:21 AM
    Amgen (AMGN) gains 5.1% on news that the biotech giant will repurchase $5B in shares via a Dutch tender offer at a price between $54 and $60.
    | Comment!
  • Oct. 24, 2011, 4:09 PM
    Amgen (AMGN): Q3 EPS of $1.40 beats by $0.11. Revenue of $3.94B (+3% Y/Y) beats by $70M. Shares +1.6% AH. (PR)
    | Comment!
  • Oct. 24, 2011, 12:10 AM
    Notable earnings after Monday's close: ALB, AMGN, CIM, FTNT, HLX, HMA, HXL, MAS, NFLX, PCL, STM, TXN, VECO, ZION
    | Comment!
  • Oct. 20, 2011, 2:13 PM
    America's most overpaid big-company CEOs based on stock market performance, according to 24/7 Wall Street: John Chambers (CSCO), Tom Ward (SD), Laurence Fink (BLK), Miles White (ABT), William Swanson (RTN), Robert Stevens (LMT), William Weldon (JNJ), Kevin Sharer (AMGN).
    | 3 Comments
  • Oct. 19, 2011, 5:02 PM
    Amgen (AMGN) says it will cut around 380 jobs to restructure its R&D organization, in what the company calls a much-needed shift in resources to late-stage development drugs. The company has a total work force of around 17,600.
    | Comment!
  • Oct. 19, 2011, 11:38 AM
    Some of the world's biggest and best-known stocks have lain comatose for years, many of them leaders in a host of industries - WMT, CSCO, PFE, INTC, GE, MSFT, AMGN, F, TWX, MDT - and among the most widely held stocks in America. More than $2T is locked up in blue chips that have gone absolutely nowhere or down for a decade.
    | 4 Comments
  • Oct. 10, 2011, 6:39 PM
    Maxygen (MAXY) gains in the post-session after it says the U.S. Patent and Trademark Office has rejected all of Amgen's (AMGN) patent claims to certain molecules that potentially cover Maxygen's MAXY-G34 drug candidate. MAXY +3.2% AH.
    | Comment!
  • Sep. 19, 2011, 11:26 AM
    Amgen (AMGN -0.4%) is outperforming a little after the FDA approves the use of its Prolia osteoporosis drug for increasing bone mass in breast cancer and prostate cancer patients. Amgen reported $44M in Prolia sales during Q2, after initially delivering sales that fell short of Street expectations.
    | Comment!
  • Jul. 29, 2011, 8:17 AM
    Amgen (AMGN): Q2 EPS of $1.37 beats by $0.08. Revenue of $3.96B (+4.1% Y/Y) beats by $180M. Sees FY'11 EPS at upper end of $5.00-5.20; Revenue at upper end of $15.1-15.5B. Shares +2.5% premarket. (PR)
    | Comment!
  • Jul. 29, 2011, 12:05 AM
    Notable earnings before Friday's open: ACI, AEP, AGP, AIV, AMGN, AON, AXL, CPN, CVH, CVX, HP, ITT, LPX, MRK, NEM, NWL, PPC, TOT, WY
    | Comment!
  • Jul. 15, 2011, 5:34 PM
    Amgen (AMGN) reaches a settlement with TEVA in its Neupogen patent-infringment lawsuit. The company had filed the claim to block Teva from selling its copycat drug Neutroval, used to prevent infections in patients receiving chemotherapy. Under the agreement, Teva will be prevented from launching Neutroval until 2013. AMGN +1.1%, TEVA -0.1% AH.
    | Comment!
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States